Use of acalabrutinib in patients with mantle cell lymphoma

Farrukh T. Awan, Wojciech Jurczak

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Introduction: Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Areas covered: This narrative review provides an overview of acalabrutinib, its use in clinical practice and potential future developments. Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL. To prepare patients for therapy, all preexisting infections should be diagnosed and treated, and infection prophylaxis undertaken. Serious adverse reactions are rare with acalabrutinib; however, patients should be made aware of common adverse events such as headaches, which usually resolve within one month without medical treatment. Interaction with other drugs appears to be less of an issue with acalabrutinib than with ibrutinib; however, patients receiving acalabrutinib therapy must be advised not to take any additional medications without first consulting with their treating physician. A key unmet medical need is treatment options for patients in whom BTK inhibitors are discontinued, because of either intolerance or refractory disease. Patients not tolerating ibrutinib could be switched to acalabrutinib, which has improved selectivity and increased tolerability. First-line treatment with acalabrutinib is being investigated.

Original languageEnglish (US)
Pages (from-to)495-502
Number of pages8
JournalExpert Review of Hematology
Volume11
Issue number6
DOIs
StatePublished - Jun 3 2018
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Therapeutics
Infection
acalabrutinib
Headache
Physicians
Pharmaceutical Preparations

Keywords

  • Acalabrutinib
  • adverse events
  • B-cell malignancies
  • Bruton tyrosine kinase inhibitor
  • efficacy
  • mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Use of acalabrutinib in patients with mantle cell lymphoma. / Awan, Farrukh T.; Jurczak, Wojciech.

In: Expert Review of Hematology, Vol. 11, No. 6, 03.06.2018, p. 495-502.

Research output: Contribution to journalReview article

@article{4915f8e984fc42eab326113cd18cd66b,
title = "Use of acalabrutinib in patients with mantle cell lymphoma",
abstract = "Introduction: Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Areas covered: This narrative review provides an overview of acalabrutinib, its use in clinical practice and potential future developments. Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL. To prepare patients for therapy, all preexisting infections should be diagnosed and treated, and infection prophylaxis undertaken. Serious adverse reactions are rare with acalabrutinib; however, patients should be made aware of common adverse events such as headaches, which usually resolve within one month without medical treatment. Interaction with other drugs appears to be less of an issue with acalabrutinib than with ibrutinib; however, patients receiving acalabrutinib therapy must be advised not to take any additional medications without first consulting with their treating physician. A key unmet medical need is treatment options for patients in whom BTK inhibitors are discontinued, because of either intolerance or refractory disease. Patients not tolerating ibrutinib could be switched to acalabrutinib, which has improved selectivity and increased tolerability. First-line treatment with acalabrutinib is being investigated.",
keywords = "Acalabrutinib, adverse events, B-cell malignancies, Bruton tyrosine kinase inhibitor, efficacy, mantle cell lymphoma",
author = "Awan, {Farrukh T.} and Wojciech Jurczak",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/17474086.2018.1473030",
language = "English (US)",
volume = "11",
pages = "495--502",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Use of acalabrutinib in patients with mantle cell lymphoma

AU - Awan, Farrukh T.

AU - Jurczak, Wojciech

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Areas covered: This narrative review provides an overview of acalabrutinib, its use in clinical practice and potential future developments. Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL. To prepare patients for therapy, all preexisting infections should be diagnosed and treated, and infection prophylaxis undertaken. Serious adverse reactions are rare with acalabrutinib; however, patients should be made aware of common adverse events such as headaches, which usually resolve within one month without medical treatment. Interaction with other drugs appears to be less of an issue with acalabrutinib than with ibrutinib; however, patients receiving acalabrutinib therapy must be advised not to take any additional medications without first consulting with their treating physician. A key unmet medical need is treatment options for patients in whom BTK inhibitors are discontinued, because of either intolerance or refractory disease. Patients not tolerating ibrutinib could be switched to acalabrutinib, which has improved selectivity and increased tolerability. First-line treatment with acalabrutinib is being investigated.

AB - Introduction: Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Areas covered: This narrative review provides an overview of acalabrutinib, its use in clinical practice and potential future developments. Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL. To prepare patients for therapy, all preexisting infections should be diagnosed and treated, and infection prophylaxis undertaken. Serious adverse reactions are rare with acalabrutinib; however, patients should be made aware of common adverse events such as headaches, which usually resolve within one month without medical treatment. Interaction with other drugs appears to be less of an issue with acalabrutinib than with ibrutinib; however, patients receiving acalabrutinib therapy must be advised not to take any additional medications without first consulting with their treating physician. A key unmet medical need is treatment options for patients in whom BTK inhibitors are discontinued, because of either intolerance or refractory disease. Patients not tolerating ibrutinib could be switched to acalabrutinib, which has improved selectivity and increased tolerability. First-line treatment with acalabrutinib is being investigated.

KW - Acalabrutinib

KW - adverse events

KW - B-cell malignancies

KW - Bruton tyrosine kinase inhibitor

KW - efficacy

KW - mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85048370976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048370976&partnerID=8YFLogxK

U2 - 10.1080/17474086.2018.1473030

DO - 10.1080/17474086.2018.1473030

M3 - Review article

C2 - 29737219

AN - SCOPUS:85048370976

VL - 11

SP - 495

EP - 502

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 6

ER -